Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 18/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 17/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30328602 | 1.00 | HCRTR2 (0.36) | HCRTR2HCRTR1OPRM1SIGMAR1PTPN11 | |
| SCHEMBL25164424 | 0.96 | HCRTR2 (0.38) | HCRTR2HCRTR1 | |
| SCHEMBL30327873 | 0.96 | HCRTR2 (0.38) | HCRTR2HCRTR1 | |
| SCHEMBL30327684 | 0.95 | HCRTR2 (0.40) | HCRTR2HCRTR1 | |
| SCHEMBL25164024 | 0.95 | HCRTR2 (0.40) | HCRTR2HCRTR1 | |
| SCHEMBL25164426 | 0.92 | HCRTR2 (0.39) | HCRTR2HCRTR1OPRM1 | |
| SCHEMBL30328559 | 0.92 | HCRTR2 (0.39) | HCRTR2HCRTR1OPRM1 | |
| SCHEMBL25164946 | 0.91 | HCRTR2 (0.37) | HCRTR2HCRTR1OPRM1SIGMAR1 | |
| SCHEMBL30328522 | 0.91 | HCRTR2 (0.37) | HCRTR2HCRTR1OPRM1SIGMAR1 | |
| SCHEMBL25164004 | 0.87 | LIPE (0.35) | HCRTR2HCRTR1OPRM1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034170-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2025-01-30 | — | — | US | disclosed |
| WO-2023064343-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2023064343-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034170-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | GBA1, GAA, GBA2 | HCRTR2 2687/4885HCRTR1 2849/4885OPRM1 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.